Literature DB >> 30304729

Effect of Leaking Foveal Microaneurysms on the Treatment of Center-Involving Diabetic Macular Edema: A Pilot Study.

Takao Hirano1, Yuichi Toriyama1, Yasuhiro Iesato1, Akihiro Ishibazawa2, Masahiko Sugimoto3, Yoshihiro Takamura4, Taiji Nagaoka2,5, Toshinori Murata6.   

Abstract

PURPOSE: Evaluate the effect of foveal leaking microaneurysms (MAs) on the required number of intravitreal ranibiz-umab (IVR) injections in the treatment of center-involving diabetic macular edema (DME) when treated with focal/grid laser.
DESIGN: A pilot study of prospective, nonrandomized, multicenter clinical trial.
METHODS: This study enrolled 21 eyes with DME for which pro re nata IVR injections were combined with short-pulse focal/grid laser. At 12 months, best-corrected visual acuity (BCVA), central subfield macular thickness (CMT), and the required number of IVRs to maintain CMT < 300 µm were compared between eyes with or without foveal leaking MAs, termed the MA(+) and MA(-) groups, respectively.
RESULTS: Significant CMT improvements (p < 0.0001) and increased BCVA of 4.0 ± 8.5 letters were observed at 12 months. The MA(-) group required significantly fewer IVRs than did the MA(+) group (mean: 4.9 ± 3.0 vs. 8.6 ± 3.0; p = 0.0306). In the latter 6 months of the 1-year follow-up, 50% (4/8) of MA(-) eyes did not require any IVR administration to sustain CMT < 300 µm.
CONCLUSIONS: A combination therapy of short-pulse focal/grid laser and reduced IVR injections appeared noninferior to previous reports of IVR monotherapy. Further large-scale investigations are warranted.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Capillary nonperfusion; Diabetic macular edema; Focal/grid laser; Short-pulse laser; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2018        PMID: 30304729     DOI: 10.1159/000492005

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  3 in total

1.  Should the outcome of focal photocoagulation for center-sparing diabetic macular edema require expanding the definition of center involvement?

Authors:  Selma Alin Somilleda-Ventura; Dulce M Razo Blanco-Hernández; Surisadai Serafín-Solís; Virgilio Lima-Gómez
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

2.  Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema.

Authors:  Takao Hirano; Yuichi Toriyama; Yoshihiro Takamura; Masahiko Sugimoto; Taiji Nagaoka; Yoshimi Sugiura; Fumiki Okamoto; Michiyuki Saito; Kousuke Noda; Shigeo Yoshida; Akihiro Ishibazawa; Osamu Sawada; Toshinori Murata
Journal:  Sci Rep       Date:  2021-02-24       Impact factor: 4.379

3.  Regional Variety of Reduction in Retinal Thickness of Diabetic Macular Edema after Anti-VEGF Treatment.

Authors:  Yutaka Yamada; Yoshihiro Takamura; Takehiro Matsumura; Makoto Gozawa; Masakazu Morioka; Masaru Inatani
Journal:  Medicina (Kaunas)       Date:  2022-07-14       Impact factor: 2.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.